StockData
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. (LXEO) stock

LXEONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$2.85−0.38 (-11.61%)

Close on Nov 17, 2026Market cap $234.24MP/E –Yield –

Lexeo Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Lexeo Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$88.37M. For fiscal 2025 it was -$98.56M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$98.56M–
FY2024Dec 31, 2024-$81.15M–
FY2023Dec 31, 2023-$59.50M–
FY2022Dec 31, 2022-$54.56M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.60M–
Q1 FY2026Mar 31, 2026-$21.14M–
Q4 FY2025Dec 31, 2025-$20.08M–
Q3 FY2025Sep 30, 2025-$29.55M–
Q2 FY2025Jun 30, 2025-$27.22M–
Q1 FY2025Mar 31, 2025-$21.72M–
Q4 FY2024Dec 31, 2024-$28.33M–
Q3 FY2024Sep 30, 2024-$17.81M–
Q2 FY2024Jun 30, 2024-$20.15M–
Q1 FY2024Mar 31, 2024-$14.87M–
Q4 FY2023Dec 31, 2023-$13.98M–
Q3 FY2023Sep 30, 2023-$13.95M–
Q2 FY2023Jun 30, 2023-$13.19M–
Q1 FY2023Mar 31, 2023-$18.37M–
Q4 FY2022Dec 31, 2022-$16.63M–

More Lexeo Therapeutics figures

See a number that looks wrong?